A qui­et car­dio up­start makes some noise, get­ting $300M from Bain and div­ing deep in­to the clin­ic — with some re­al mon­ey for pipeline deals

The small ex­ec­u­tive team at Car­du­ri­on has been stick­ing care­ful­ly to its goals, in-li­cens­ing a lead car­dio drug from Astel­las in 2018 and mak­ing a care­ful trek in­to hu­man stud­ies as they ad­vanced a fol­low-up pro­gram and grad­u­al­ly built out an­oth­er pre­clin­i­cal prospect.

In­volved in one of the most grind­ing­ly tough fields in drug R&D, they nev­er thought much of tout­ing their work. They did deals with Take­da and Pfiz­er with­out mak­ing much of a show of it. Even es­tab­lished a small op­er­at­ing unit in Japan. Po­laris in­vest­ed, but no one ever said how much — or much about why.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN